JAK2 and essential thrombocythemia: Conversely, antiplatelets are avoided by physicians, mostly in cases of ET patients < 60 years who are JAK2-negative and without prior thrombosis (69.2%), who are young (<40 years of age) (50%), and CALR-mutated (23.1%).